CompletedNot Applicable

Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer

France16 participantsStarted 2020-11-26

Plain-language summary

Activating somatic mutations and methylation profiles identified by liquid biopsies could identify CDH1 and CTNNA1 pathogenic variants carriers with invasive diffuse gastric cancer undetectable by upper G-I endoscopy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Case: * Patient ≥ 18 years old * CDH1 or CTNNA1 germline pathogenic variant. * No history of diffuse gastric cancer. * French social security. * Ability to understand and willingness to sign a written informed consent document. Volunteers: * Patients ≥ 18 years old * Patients with no oncological history * Patients with macroscopically normal oeso-gastroduodenal fibroscopy * French social security. * Ability to understand and willingness to sign a written informed consent Exclusion Criteria: for both arms * Patients with cancer being treated * Patients with metastatic cancer * Medical contraindication to general anesthesia or FOGD (bleeding disorder, pregnant women ) * Patients under guardianship or curator

What they're measuring

Number of subjects in whom somatic mutations or methylation profiles are detected.

Timeframe: Over two years of surveillance

Trial details

NCT IDNCT04253106

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-10

View on ClinicalTrials.gov More Hereditary Diffuse Gastric Cancer trials